#United States #New Haven #Trevi Therapeutics #Haduvio #RIVER trial

Trevi Therapeutics to Unveil Promising Data from RIVER Trial at ERS 2025

Trevi Therapeutics, Inc., a biopharmaceutical firm focused on developing innovative therapies, is set to present key results from its Phase 2a RIVER trial at the upcoming European Respiratory Society (ERS) Congress 2025, scheduled to take place from September 27 to October 1 in Amsterdam, Netherlands. The trial explores Haduvio™ (oral nalbuphine ER), a groundbreaking treatment aimed at addressing chronic cough among patients suffering from idiopathic pulmonary fibrosis (IPF) and other chronic cough-related conditions.

Highlights from the RIVER Trial

The RIVER trial, which stands for Refractory Chronic Cough Improvement Via Nalbuphine ER, is a randomized, double-blind, placebo-controlled study. This trial was designed to assess the efficacy, safety, and tolerability of nalbuphine ER, particularly for patients impacted by refractory chronic cough (RCC). Poster presentations at the Congress will cover two significant aspects of the trials:

1. Efficacy and Safety of Nalbuphine ER: Presentations will document the outcomes for patients on nalbuphine ER compared to a placebo, focusing on the safety profile and overall effectiveness during the trial.
2. Responder Analysis: This session will analyze the responders to nalbuphine ER treatment within the cohort, providing a detailed look at those who exhibited significant improvements in their cough conditions.

The Unmet Need for RCC Treatments

RCC presents a considerable challenge in respiratory care, with many patients struggling with a persistent cough lasting over eight weeks despite receiving treatment for underlying conditions—conditions such as asthma or gastroesophageal reflux disease. Studies estimate that around 2-3 million individuals in the U.S. are afflicted with this debilitating ailment, which can drastically affect their quality of life. Currently, there are no FDA-approved medications targeting RCC, underscoring the urgent need for effective treatments.

The RIVER trial aims to fill this gap by evaluating the therapeutic potential of Haduvio. During the randomized study design, patients underwent multiple treatment periods with various dosages of nalbuphine ER, making it pivotal to their recovery.

Trevi's Commitment to Innovative Solutions

Trevi Therapeutics remains committed to addressing unmet medical needs within the respiratory illness landscape. The data being presented at the ERS Congress not only showcases the company's dedication to research and clinical excellence but also its unwavering focus on improving patient outcomes in the realm of chronic cough management.

As the congress unfolds, insights gained from these presentations will be vital in shaping future treatment paradigms and can provide a potential breakthrough for patients suffering from RCC. For those eager to follow Trevi's journey, updates will be available on their official website and social media channels.

Conclusion

The anticipation surrounding Trevi Therapeutics' presentations at the ERS Congress is palpable within the medical community. As new data emerges, there is hope that therapies like Haduvio™ will lead to significant advancements in the treatment landscape for patients suffering from chronic cough due to IPF and other conditions. This event marks a crucial step in potentially bringing forward solutions to those afflicted by RCC, aiming for a brighter, cough-free future.

For more detailed information regarding their findings, keep an eye on Trevi's official channels.

For inquiries related to investor relations, please contact Jonathan Carlson at Trevi Therapeutics, or for media inquiries, reach out to Rosalia Scampoli.